Alvotech · NASDAQ:ALVO
Alvotech — 9M 2026 Earnings Presentation
31 slides from Alvotech's earnings presentation, Nov 12, 2026

Slide 1: 9M 2026 Financial Results
z z 9M 2026 Financial Results NOVEMBER 12, 2026

Slide 2: Disclaimer
Disclaimer This presentation (“Presentation”) does not contain or constitute an offer a fact or probability. Alvotech does not undertake any duty to update other revenue, gross margin, product margin, Adjusted EBITDA, Adjusted to sell, a solicitation of an offer to buy, or a recommendation to purcha

Slide 3: Agenda
Agenda 1 OPENING REMARKS Róbert Wessman | Executive Chairman z z 2 BUSINESS UPDATE Lisa Graver | Chief Executive Officer 3 REGULATORY AND R&D UPDATE Joseph McClellan | Chief Operating Officer 4 FINANCIAL RESULTS Linda Jónsdóttir | Chief Financial Officer 5 Q&A Lisa Graver, Joseph McClellan and Linda

Slide 4: Opening remarks
z zz Opening remarks ROBERT WESSMAN, Executive Chairman

Slide 5: Business update
zz z Business update LISA GRAVER, Chief Executive Officer

Slide 6: Adjusted financial results highlights 9M 2026
Adjusted financial results highlights 9M 2026 TOTAL REVENUE GROSS MARGIN FY 2026 GUIDANCE $323m 54% vs. $420m in 9M 2025 –23% vs. 59% in 9M 2025 Total revenue $650-700m z EBITDA CASH BALANCE ON SEPTEMBER 30 EBITDA $78m $61m $180-220m vs. $68m in 9M 2025 +15% vs. $172m at YE 2025 Performance expected

Slide 7: Recent progress across three drivers of value creation
Recent progress across three drivers of value creation Commercial recovery progressing; strategic advances strengthen future growth potential COMMERCIAL PIPELINE MANUFACTURING Sequential improvement Platform validation Supply resilience ✓ Q3 product and service ✓ Applications for both IV & SC ✓ FDA

Slide 8: Established franchises in expanding biosimilars markets
Established franchises in expanding biosimilars markets AVT02 and AVT04 combine strong U.S. market positions with sustained European demand UNITED STATES EUROPE AVT02 NO. 2 BIOSIMILAR POSITION SUSTAINED DEMAND (adalimumab) SIMLANDI® is supported HUKYNDRA® continues to by strong U.S. demand perform a

Slide 9: Newer launches broadening the commercial base
Newer launches broadening the commercial base AVT05, AVT06 and AVT03 expand market reach AVT05 (golimumab): AVT06 (aflibercept): AVT03 (denosumab): bSimponi® bEylea® bProlia® / bXgeva® 13 EU MARKETS 10+ EU MARKETS EUROPE + JAPAN z Launched across key European Broad European and Japanese An additiona

Slide 10: Lotus partnership opens new route to U.S. commercialization
Lotus partnership opens new route to U.S. commercialization Evolving the commercial model to capture more value from selected pipeline assets A NEW C O MMERC IAL MO D EL UP TO TWO ROUTES INTO THE U.S. MARKET Alvotech retains the right to commercialize directly alongside Lotus $150m Potential upfront

Slide 11: Regulatory and R&D update
zz z Regulatory and R&D update JOSEPH MCCLELLAN, Chief Operating Officer

Slide 12: October FDA approvals strengthen SIMLANDI manufacturing
October FDA approvals strengthen SIMLANDI manufacturing Two distinct advances at the Reykjavík facility DSM2 MANUFACTURING APPROVAL PROCESS 2.0 APPROVAL 2 U.S.-approved drug substance suites >2× output per batch z Enables SIMLANDI drug substance for More than doubles SIMLANDI drug substance the U.S.

Slide 13: US regulatory momentum ahead of three FDA decisions
US regulatory momentum ahead of three FDA decisions JUN 2026 BLA RESUBMISSIONS AVT05 and AVT06 by Alvotech; AVT03 by Dr. Reddy’s. JUL 2026 FDA SURVEILLANCE CLOSEOUT Inspection closed with a VAI classification. z OCT 2026 SIMLANDI MANUFACTURING APPROVALS FDA approval of DSM2 and Process 2.0. DEC 2026

Slide 14: Global manufacturing network strengthens supply resilience
Global manufacturing network strengthens supply resilience Core platform complemented by strategic external manufacturing relationships REYKJAVÍK FUJIFILM LOTTE BIOLOGICS ICELAND UNITED STATES UNITED STATES Core platform Second-source capability Strategic partnership Integrated development and Addit

Slide 15: Industry leading, internally developed R&D pipeline
Industry leading, internally developed R&D pipeline In addition to the named programs, Alvotech has developed 20+ cell lines, providing a range of opportunities BIOSIMILAR CANDIDATE REFERENCE THERAPEUTIC EARLY PHASE PRE-CLINICAL CLINICAL UNDER BIOLOGIC AREA DEVELOPMENT REVIEW1 AVT16/802 vedolizumab

Slide 16: AVT16/AVT80 – proposed biosimilars to Entyvio (vedolizumab)
AVT16/AVT80 – proposed biosimilars to Entyvio® (vedolizumab) PROGRAM MILESTONES → FDA: BLAs for AVT16 (IV) and AVT80 (SC, prefilled syringe and autoinjector) accepted for review $7B → EMA: single validated application covering IV and SC under TAM1 review z OVERVIEW → Addressing inflammatory bowel di

Slide 17: AVT29 – proposed biosimilar to Eylea HD (aflibercept 8 mg)
AVT29 – proposed biosimilar to Eylea HD® (aflibercept 8 mg) PROGRAM MILESTONES → EMA: AVT29 validated as a MYNZEPLI line extension, the first known Eylea 8 mg biosimilar filing $4B → Pivotal safety and efficacy study underway to support US regulatory submission in 2028 TAM1 → Potential first-wave en

Slide 18: Financial results
zz z Financial results LINDA JONSDOTTIR, Chief Financial Officer

Slide 19: Financial highlights for the quarter: Executive summary 3Q26
Executive summary 3Q26 Financial highlights for the quarter Adjusted total revenue Gross margin Product margin → Adjusted total revenues of $112m, up USD m % of adj. total revenues % of adj. product revenues 5% QoQ. Product supply increasing, -2% +5% -15 +3 +19 +6 resulting in higher product sales,

Slide 20: Financial highlights for the first nine months: Executive summary 9M26
Executive summary 9M26 Financial highlights for the first nine months Adjusted total revenues Gross margin Product margin → Adjusted total revenues down by 23% YoY USD m % of adjusted total revenues % of adjusted product revenues at $323m, driven by lower milestone -23% 69 -5 -18 revenues and impact

Slide 21: Revenues and Adj. EBITDA margin
Revenues and 9M26 shows even split between product Adj.EBITDA margin revenue and licensing revenues → Product revenues increased each Adjusted total revenues and Adjusted EBITDA margin quarter, totaling $164m for 9M26. The USD m, % of revenues 30% YoY decline reflects lower first-half Adj. EBITDA ma

Slide 22: Cash flow
Cash flow in the quarter mainly impacted Cash flow by working capital related to ramp up of production → Cash from operations in 3Q26 positive Cash from operations Cash balance $27m, increasing by $10m QoQ (2Q26: USD m USD m $17m) 17 172 143 → Working capital absorbed $116m in 3Q26, reflecting inven

Slide 23: Balance sheet: Assets
Balance sheet: Unaudited condensed consolidated interim Assets financial statements as of September 30, 2026 ASSETS → Pipeline development: intangible assets up $93m to $174m through qualifying development capitalization. → Investment: property, plant and equipment increased by $11 million z from ye

Slide 24: Balance sheet: Equity & liabilities
Balance sheet: Unaudited condensed consolidated interim Equity & liabilities financial statements as of September 30, 2026 EQUITY AND LIABILITIES → Equity funding: $156m of net capital contributions narrowed the equity deficit to $267m. → Debt supported working capital and pipeline investment. z → W

Slide 25: Outlook for full-year 2026
Outlook for full-year 2026 Performance expected toward the lower end of the range ADJUSTED TOTAL REVENUE $650-700m ADJUSTED EBITDA $180-220m ADJUSTED TOTAL REVENUE ADJUSTED EBITDA USD m +14%1 USD m +46%1 z +21% 650-700 +27% 180-220 +429% 593 137 108 492 -205 -291 +9% 85 93 2022 2023 2024 2025 2026F

Slide 26: Focused on execution, building for long-term growth
Focused on execution, building for long-term growth DELIVER PLANNED EXPAND PRODUCT PORTFOLIO SUPPLY CONTRIBUTION Translate strengthened Drive growth across an manufacturing capabilities into expanding range of products planned Q4 deliveries and markets z EXECUTE ADVANCE REGULATORY STRATEGIC MILESTON

Slide 27: Additional information and contacts
Additional information and contacts Investor meeting We want to Financial calendar Follow us and live webcast hear from you! & upcoming events for more z Alvotech will conduct a business Balaji Prasad UBS Global Biopharma Conference, Register to receive press releases, update conference call and liv

Slide 28: Appendix
A alvotech Appendix

Slide 29: Reported to Adjusted Reconciliation – 9 Month Basis
Reported to Adjusted Reconciliation – 9 Month Basis 9M 2026 9M 2025 9M 2026 Adjustment Entries Adjustment Adjustment $ millions Reported Adjusted Reported Adjusted Entries Entries − $0.4m charge related to long-term incentive plan (non-cash) Cost of Product Revenue − $0.7m cost related to workforce

Slide 30: Reported to Adjusted Reconciliation – Quarterly Basis
Reported to Adjusted Reconciliation – Quarterly Basis z © Alvotech. All rights reserved 30

Slide 31: Capital structure
Capital Common shares outstanding and total potential structure dilution as of September 30, 2026 Shares millions September 30 June 30 March 31 December 31 September 30 Change YoY% › This table reflects instruments that could 2026 2026 2026 2025 2025 potentially create dilution for EPS purposes unde
Source: company website
More decks from Alvotech
H1 2026 Earnings Presentation31 slides · Aug 20, 2026
Q1 2026 Earnings Presentation21 slides · May 7, 2026
FY2025 Earnings Presentation19 slides · Mar 19, 2026
FY2025 Earnings Presentation36 slides · Mar 19, 2026
Q3 2025 Earnings Presentation23 slides · Nov 13, 2025
Q2 2025 Earnings Presentation12 slides · Aug 14, 2025